RESEARCH 研究の報告

2025.4.30

Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer.

著者 Hashimoto K, Kaira K, Mouri A, Shiono A, Miura Y, Yamaguchi O, Imai H, Kagamu H, Kuji I.

Transl Lung Cancer Res. 2025 Apr 30;14(4):1242-1253. doi: 10.21037/tlcr-2024-1084. Epub 2025 Apr 27.

PMID: 40386730

2025.4.23

Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer.

著者 Shiono A, Imai H, Endo S, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.

Mol Clin Oncol. 2025 Apr 23;22(6):58. doi: 10.3892/mco.2025.2853. eCollection 2025 Jun.

PMID: 40322546

2025.4.1

A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab.

著者 Mouri A, Imai H, Endo S, Nakagawa J, Tsukamoto K, Kurata Y, Yamaguchi O, Masaki K, Hashimoto K, Shiono A, Miura Y, Kobayashi K, Kaira K, Kagamu H.

Cancer Med. 2025 Apr;14(8):e70741. doi: 10.1002/cam4.70741.

PMID: 40249663

2025.2.1

Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer.

著者 Matsukida A, Imai H, Shiono A, Ryuno Y, Hashimoto K, Miura YU, Endo S, Okazaki S, Yamaguchi OU, Mouri A, Abe T, Kaira K, Kobayashi K, Kato S, Kagamu H.

Anticancer Res. 2025 Feb;45(2):733-741. doi: 10.21873/anticanres.17461.

PMID: 39890195

2025.1.23

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.

著者 Endo S, Imai H, Mouri A, Tsukamoto K, Masaki K, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, Nakagawa J, Kaira K, Kobayashi K, Kagamu H.

J Cancer Res Clin Oncol. 2025 Jan 23;151(1):43. doi: 10.1007/s00432-025-06089-x.

PMID: 39843575

2025.1.15

Current drug therapy for pleural mesothelioma.

著者 Imai H.

Respir Investig. 2025 Mar;63(2):200-209. doi: 10.1016/j.resinv.2024.12.017. Epub 2025 Jan 15.

PMID: 39818191

2025.1.4

Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529).

著者 Tokito T, Yamada K, Ishii H, Takiguchi Y, Saito G, Minato K, Imai H, Tanaka H, Miura S, Watanabe K, Koreeda Y, Ono A, Furuya N, Misumi T, Hayakawa K, Ogo E, Okamoto H.

Radiat Oncol. 2025 Jan 4;20(1):2. doi: 10.1186/s13014-024-02577-5.

PMID: 39755666

2024.12.4

Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare Case.

著者 Mikami E, Hashimoto K, Kaira K, Mouri A, Miura Y, Shiono A, Yamaguchi O, Imai H, Kagamu H.

Cureus. 2024 Dec 4;16(12):e75079. doi: 10.7759/cureus.75079. eCollection 2024 Dec.

PMID: 39759665

2024.11.18

Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer.

著者 Hashimoto K, Kaira K, Imai H, Yamaguchi O, Mouri A, Shiono A, Miura Y, Kobayashi K, Kagamu H, Kuji I.

Cancer Imaging. 2024 Nov 18;24(1):157. doi: 10.1186/s40644-024-00800-w.

PMID: 39558409

2024.9.15

Prognostic significance of LAT1 expression in pleural mesothelioma.

著者 Taguchi R, Kaira K, Miura Y, Umesaki T, Mouri A, Imai H, Kagamu H, Yasuda M, Kanai Y, Nitanda H, Ishida H, Sakaguchi H.

Heliyon. 2024 Sep 3;10(17):e37414. doi: 10.1016/j.heliyon.2024.e37414. eCollection 2024 Sep 15.

PMID: 39290273

2024.9.1

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.

著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.

Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.

PMID: 39287161

2024.8.5

The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.

著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.

Oncology. 2025;103(2):83-93. doi: 10.1159/000540651. Epub 2024 Aug 5.

PMID: 39102792